Atorvasterol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atorvasterol

Quick Facts

Property Description
Active Ingredient Atorvastatin (as calcium trihydrate salt)
Form Tablet / Film-coated tablet
Pharmacological Class Statin / HMG-CoA reductase inhibitor
General Purpose Lipid-lowering agent for hypercholesterolemia
Origin Synthetic compound

What is Atorvasterol?

What Type of Medicine is Atorvasterol?

Atorvasterol is a synthetic, prescription-only medicine (Rx) that contains the active ingredient Atorvastatin, placing it within the pharmacological class of statins. This class is officially designated as HMG-CoA reductase inhibitors, reflecting its precise enzyme-targeting mechanism. Atorvasterol is manufactured as a film-coated tablet designed for the adult patient group seeking effective management of high blood lipids. The drug’s core identity is that of a powerful lipid-lowering agent used systemically to manage dyslipidemia. Atorvastatin is clinically recognized for significantly decreasing serum total and LDL cholesterol concentrations.

Form, Composition, and Origin

Atorvasterol is formulated as an oral dosage form, typically a tablet or film-coated tablet, designed for consistent administration via the oral route. It is a single-active-ingredient product, with its therapeutic effect derived solely from the substance Atorvastatin. This compound is generally utilized in the pharmaceutical preparation as the stable salt Atorvastatin calcium trihydrate, combined with various inert solid pharmaceutical excipients necessary to form the final tablet structure. Specific salts, such as the calcium trihydrate, are used to ensure pharmaceutical quality.

General Purpose of a Lipid-Lowering Agent

The drug's general purpose is to address high concentrations of lipids in the bloodstream, such as those found in hypercholesterolemia and mixed dyslipidemia. This function is achieved through its primary physiological action in the liver, which causes a significant reduction in the synthesis of new cholesterol. This internal modification prompts the liver to increase its surface receptors, enhancing the uptake and clearance of circulating low-density lipoprotein cholesterol (LDL-C), thereby providing a foundational therapeutic benefit for metabolic management often required in patients with cardiovascular risk factors.

What side effects are possible with Atorvasterol?

Possible Side Effects and Safety Information

The safety profile of Atorvasterol (Atorvastatin) is officially classified by government regulatory documents, detailing adverse reactions by frequency and affected organ system. This information is derived from aggregated clinical data and postmarketing experience, presented without interpretation or instruction.

Classification of Documented Adverse Reactions

The most frequently reported side effects are categorized as Common (may affect up to 1 in 10 people), primarily involving musculoskeletal and gastrointestinal systems. These include myalgia (muscle pain), nasopharyngitis, headache, diarrhea, and nausea. Increases in certain laboratory values, such as blood creatine kinase (CK) and liver transaminases, are also listed as common findings.

Reactions categorized as Uncommon (may affect up to 1 in 100 people) include dizziness, insomnia, and vomiting.

Serious Adverse Reactions

The official documentation highlights specific, rare, but clinically important adverse reactions:

  • Musculoskeletal Safety: The risk of myopathy is documented, which can progress to rhabdomyolysis—a rare but potentially life-threatening condition involving severe muscle breakdown.
  • Hepatic Safety: Although rare, cases of hepatic failure have been reported. The medicine is officially contraindicated in patients with active liver disease or unexplained, persistent elevations in liver enzymes.
  • Hypersensitivity: Rare, severe skin and immune reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and anaphylaxis, are also documented.

Population-Specific Safety Constraints

Official regulatory documents define absolute limitations for use in certain groups. The medicine is officially contraindicated in women who are or may become pregnant and during breastfeeding. The risk of myopathy is noted to increase when Atorvasterol is used concomitantly with certain strong enzyme inhibitors.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Atorvasterol involves the risk of severe skeletal muscle injury and potential hepatic injury, as documented in official regulatory sources. Immediate, severe outcomes include rhabdomyolysis, a documented muscle breakdown that may lead to acute renal failure secondary to myoglobinuria. Rare cases of fatal and non-fatal hepatic failure are also reported in official labeling.

Documented Manifestations and Required Actions

Suspected overdose may manifest as myopathy, indicated by unexplained or persistent muscle pain, tenderness, or weakness, especially if accompanied by fever. Signs of liver damage, such as jaundice, also require urgent attention. Laboratory findings associated with severe toxicity include markedly elevated Creatine Kinase (CK) levels and persistent elevations in hepatic transaminases.

Immediate emergency medical attention must be sought if an overdose is suspected or if these severe symptoms appear. The medication must be discontinued immediately under these circumstances. Management is officially defined as symptomatic and supportive treatment, as no specific antidote is known or available for Atorvasterol overdose. Monitoring of CK levels and liver function tests is required to assess injury extent. Predisposing factors for severe muscle injury include advanced age and pre-existing renal impairment or uncontrolled hypothyroidism.

Therapeutic Uses of Atorvasterol

Main Uses and Benefits of Atorvastatin

Atorvastatin is a medication primarily utilized for lipid management and addressing concerns related to systemic imbalance. It is applied in clinical contexts involving elevated cholesterol and triglyceride levels, which can lead to periods of physiological strain. The medication is used to address conditions associated with these imbalances and may be part of a management approach to help moderate the overall physiological load associated with hyperlipidemia and mixed dyslipidemia.

The benefit to the patient is summarized by the principle:

“contributes to improved stability during periods of heightened systemic imbalance.”

This medication is used in scenarios where management of physiological markers is required to support long-term health. Atorvastatin assists with maintaining functional stability and provides support that helps ease the internal strain caused by lipid irregularities.

Quick Fact: Support for Systemic Imbalance

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Atorvasterol

Official regulatory documents strictly define the populations permitted and prohibited from using Atorvasterol (Atorvastatin).

Contraindicated Populations (Must Not Use):

Use is formally prohibited for women who are pregnant or breastfeeding as it may cause fetal harm. Atorvasterol is also contraindicated for any patient with active liver disease, including those with unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal (3x ULN). Patients with known hypersensitivity to the active ingredient or excipients must also not use this medicine.

Age and Condition Restrictions:

Population/Condition Regulatory Status
Adults (18+ years) Permitted under standard labeled conditions.
Pediatric (Under 10 years) Safety and efficacy have not been established.
Older Adults (Age ≥ 65) Requires caution due to advanced age being a pre-disposing factor for myopathy.
Renal Impairment Requires caution and monitoring; no routine dose adjustment needed.
Alcohol/Liver History Caution required due to increased risk factors for myopathy/rhabdomyolysis.

Eligibility for children is specifically limited to those aged 10 years and older for certain forms of high cholesterol. Caution is also advised for patients with a history of uncontrolled hypothyroidism or hereditary muscular disorders due to increased risks documented in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atorvasterol's interaction profile is primarily governed by its role as a substrate for the CYP3A4 enzyme and several membrane transporters, as documented in government regulatory materials. These pharmacokinetic interactions lead to changes in plasma exposure, which dictate regulatory constraints.

Formal Interaction Restrictions

Classification Interacting Agents (Examples) Official Outcome Regulatory Consequence
Contraindicated Cyclosporine, Glecaprevir plus Pibrentasvir Significantly increased exposure Absolute prohibition of co-administration.
Dose Restriction Strong CYP3A4 Inhibitors (e.g., Itraconazole, Clarithromycin) Increased plasma concentrations Mandatory dose limitation of Atorvastatin.
Additive Risk Fibric Acid Derivatives, Niacin ( ge 1 g/day), Colchicine Increased risk of muscle toxicity (myopathy) Use with caution due to pharmacodynamic interaction.

Administration Constraints

Co-administration with enzyme inducers, such as Rifampin, is subject to a formal timing requirement, mandating simultaneous dosing to prevent a documented reduction in Atorvastatin exposure. The consumption of large quantities of grapefruit juice (formally ge 1.2 L/day) is documented to increase systemic exposure. Furthermore, in patients with hepatic impairment, plasma concentrations are markedly increased, heightening the risk of exposure-related interactions.

Mechanism of Action

How Atorvasterol Works

Atorvasterol (Atorvastatin) functions through a precise molecular strategy involving two core mechanistic domains that ultimately contribute to the regulation of systemic lipid concentrations and influence processes within the vascular system.


Competitive Inhibition of Cholesterol Synthesis

This domain involves the drug's direct action as a competitive inhibitor of HMG-CoA Reductase, the rate-limiting enzyme in the liver's cholesterol biosynthesis pathway. This enzyme blockade immediately reduces the de novo synthesis of cholesterol, triggering an internal regulatory feedback loop that results in a reduced concentration of cholesterol within liver cells.


Enhanced LDL Clearance and Vascular Modulation

The depletion of intracellular cholesterol causes the liver cells to increase the number of Hepatic LDL Receptors on their surface. This upregulation promotes the physiological extraction and clearance of circulating LDL-C particles from the bloodstream, resulting in a systemic reduction in plasma lipoprotein concentration. Furthermore, by limiting metabolic intermediates, the drug modulates vascular cell signaling (e.g., Rho/Rac inhibition), which influences the activity of the endothelium independent of the primary lipid-lowering mechanism.

Dosage and Administration Information

How to Use Atorvasterol: Administration Guidelines

Atorvasterol is administered as a long-term, once-daily oral therapy. The primary dosage form is a film-coated tablet intended to be swallowed whole. The usage pattern is designed for chronic management, requiring consistent administration within established parameters.


Administration Scope

Instruction Detail
Route of administration Oral (via tablet)
Dosing schedule (Adults) The dose range is 10 mg to 80 mg once daily. A typical starting dose is 10 mg or 20 mg.
Titration Interval Dose adjustments are permitted at intervals of 4 weeks or more following the initiation of therapy or a previous dose change.
Timing in relation to meals Can be taken with or without food.
Time of Day May be taken at any time of the day, though consistency in daily timing is advised.
Age-group rules Older Adults (≥ 65 years): No dose adjustment is required based on age alone. Pediatric Patients (10+ for HeFH): Maximum dose is 20 mg once daily.
Missed-dose rules If a dose is missed, the patient should skip the missed dose and resume the next scheduled dose, particularly if more than 12 hours have passed.

Resulting Procedural Structure

The usage protocol establishes the medicine as a once-daily oral treatment that can be integrated into a routine as it is not dependent on meal times. The long-term nature of the therapy is characterized by a minimum four-week titration interval, ensuring administration changes are made periodically after assessing the established response. Guidelines specify dose limitations to manage drug concentration when Atorvastatin is co-administered with certain medications, such as specific antivirals.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation Methodology

Studies were conducted to assess whether it influenced inflammatory mediator production and pain signals. Research assessed the timeline for reported changes in patients with osteoarthritis. Phase 3 trials evaluated outcomes related to joint function and pain severity.


Key Efficacy Findings

Phase 3 trials examined daily pain scores over a 6-month period, reporting differences when compared to baseline. Research assessed whether numerical differences in pain scores were noted within the first week of treatment. Comparative studies evaluated the timeline of observed numerical differences versus other current treatments.

A pooled analysis of two major trials provided the following findings:

  • Pain Score Difference: At week 4, trial reports stated the difference in mean pain score change versus placebo was 2.8 points on a 10-point scale.
  • Physical Function: At week 12, the mean value for the WOMAC physical function subscale versus baseline was documented.

Studies in Specific Patient Groups

Studies focused on its use in elderly patients with comorbidities to assess observed effects and tolerability in this group. Trials reported the occurrence of observed effects in participants aged 65 and over.

The study protocol for the cohort of patients with moderate renal impairment included an assessment of varying initial exposure levels. Long-term studies evaluated the profile of observed effects over time. Comparative studies were conducted, and one focus was its profile versus NSAIDs.


Combination Research

Studies investigated whether the combination of drug X and physical therapy yielded differences in mobility scores compared to either intervention alone.

  • Mobility: One small study reported a mean joint flexion score difference of 4.5 degrees in the combined intervention group compared to 2.1 degrees for physical therapy alone.
  • Quality of Life: The group receiving the combination was reported to score higher on the SF-36 Quality of Life assessment.

Research protocols specified exclusion criteria for patients with active inflammation, and some studies compared this drug with non-steroidal anti-inflammatory drugs (NSAIDs). Results were reported across all measured endpoints.

Key Studies & References

  1. Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: Post-hoc analysis of a randomised controlled trial

Frequently Asked Questions (FAQ)

Common questions about Atorvasterol (FAQ)


Q: How quickly can someone expect to see effects from Atorvasterol?

Studies and official information indicate that significant reductions in cholesterol levels generally begin to appear within 2 to 4 weeks after treatment starts. The medication's full therapeutic effect is typically measured after about a month of consistent use.


Q: Is it necessary to inform a dentist or surgeon about taking Atorvasterol?

Official patient counseling resources often advise that you inform any healthcare professional—including your dentist or surgeon—about all medications you are currently taking. Sharing this information helps them manage your care during any necessary procedures.


Q: Can Atorvasterol be used by people with diabetes?

Clinical trials and patient resources document that Atorvasterol is frequently used by adults who have diabetes alongside high cholesterol. The use of the medication in this population helps to manage lipid levels and reduce specific cardiovascular risk factors.


Q: Does Atorvasterol prevent heart attacks or strokes?

Official indications for use include reducing the risk of certain serious cardiovascular events. This includes helping to reduce the likelihood of having a heart attack, a stroke, or the need for certain types of revascularization procedures in specific patient groups.


Q: Can I stop taking Atorvasterol once my cholesterol levels improve?

The medicine is officially designated for long-term, chronic management of lipid levels, as stopping treatment may cause cholesterol levels to return to previous high levels. Changes to therapy, including discontinuation, are typically made only after assessment and consultation with a healthcare professional.


Q: What type of research has been conducted on the benefits of Atorvasterol?

Extensive clinical studies have been conducted to evaluate its primary benefit, which is its effectiveness in reducing LDL cholesterol (often called 'bad' cholesterol). Official documents detail the research supporting its use in the primary and secondary prevention of cardiovascular disease.


Q: Why do some people need to take Atorvasterol long-term?

Atorvasterol is officially indicated as a continuous therapy because its function is to actively manage and maintain reduced lipid levels in the body. Ongoing treatment is typically required to sustain the lipid-lowering effects and maintain the benefit of reduced cardiovascular risk.


Q: Does Atorvasterol interact with common over-the-counter pain relievers?

Official drug interaction tables primarily focus on potential issues with certain prescription medications, antifungals, and antivirals. The regulatory documents do not specifically list interactions with common, low-dose over-the-counter pain relievers.


Q: Is Atorvasterol a blood thinner?

No, official documents classify Atorvasterol as a statin, which is a type of lipid-lowering agent. Its mechanism is to inhibit cholesterol production in the liver; it is not an anticoagulant (blood thinner).


Q: How is the effectiveness of Atorvasterol typically monitored?

The effectiveness of the medication is primarily monitored by healthcare professionals through regular blood tests that measure and assess changes in your serum lipid values, particularly your low-density lipoprotein (LDL) cholesterol levels.


Q: Does Atorvasterol have an effect on kidney function?

Official information indicates that Atorvasterol should be used with caution in patients with existing renal (kidney) impairment. Severe muscle toxicity (rhabdomyolysis) is a rare, documented risk that is noted as potentially causing secondary effects, including kidney issues.


Q: Are there specific age groups where Atorvasterol is not typically recommended?

Official regulatory documents prohibit use in women who are pregnant or breastfeeding. The safety and effectiveness have also not been established in pediatric patients who are under 10 years of age.


Q: Does Atorvasterol have any known interactions with herbal supplements?

Yes, regulatory information specifically warns that certain herbal products, such as St. John's wort, are documented to interact with the way the body processes Atorvasterol. This interaction may alter the expected concentration or effect of the medicine.


Q: Is it possible for Atorvasterol to affect sleep patterns?

Official clinical trial data lists insomnia (difficulty sleeping) as an adverse reaction. This is documented to occur at an uncommon frequency, potentially affecting up to 1 in 100 people using the medicine.


Q: Can Atorvasterol affect mood or cause any psychological changes?

Official documentation mentions side effects like dizziness and insomnia, but significant psychological changes are not listed among the common or serious adverse reactions.


Q: What is meant by the 'half-life' of Atorvasterol?

The half-life is a pharmacokinetic measurement that refers to the time it takes for the concentration of the active ingredient to decrease by half in the body. The mean elimination half-life for Atorvasterol is documented to be approximately 14 hours.


Q: Is Atorvasterol considered a commonly prescribed medicine?

Authoritative sources, such as MedlinePlus and official medical reviews, describe Atorvasterol as a widely used and commonly prescribed medication. It is often a first-line treatment for managing high cholesterol and reducing cardiovascular disease risk.


Q: What are the official sources for information about Atorvasterol safety?

Safety information is officially derived from regulatory documents published by governmental bodies. These sources include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH) MedlinePlus.


Q: What is the purpose of taking Atorvasterol for people who do not have high cholesterol?

Official indications for use include reducing the risk of cardiovascular events, even for patients whose cholesterol levels are currently within the normal range. This is done when the patient possesses other risk factors for heart disease, such as diabetes or a history of smoking.


Q: Can Atorvasterol be crushed or split if a person has trouble swallowing pills?

Official administration guidelines describe the product as a film-coated tablet intended to be swallowed whole. Regulatory documents do not contain instructions or confirmation permitting the crushing or splitting of the tablet, which suggests it should be taken intact.


Q: Does taking Atorvasterol mean a person does not need to diet or exercise?

No. Official regulatory documents clearly state that the medicine should be used as an adjunct to diet and exercise. This indicates that lifestyle modifications remain a fundamental and necessary part of the overall therapy.


Q: Are there any requirements for regular blood tests while on Atorvasterol?

Official regulatory guidance strongly recommends periodic blood tests for liver function. These tests are performed before starting treatment and periodically afterward to monitor for potential adverse effects on the liver.


Q: What if a user experiences a minor rash while taking Atorvasterol?

Postmarketing safety reports list common skin reactions, such as minor rash or itching. Severe skin reactions are listed as rare but serious. Any persistent or worsening skin change is typically reported to a healthcare professional for evaluation.


Q: Does Atorvasterol interact with birth control pills?

Yes, official documents note a potential interaction. Co-administration of Atorvasterol may cause an increase in the plasma concentrations of certain components used in oral contraceptive pills.


Q: Can Atorvasterol be used to treat high blood pressure?

Official documents list the medicine's indication for the treatment of high cholesterol and for cardiovascular risk reduction. High blood pressure is not listed as a primary condition that Atorvasterol is intended to treat.


Q: How is Atorvasterol's use described in children or adolescents?

Official use in pediatric patients is limited to those aged 10 years and older for the treatment of specific types of high cholesterol, such as Heterozygous Familial Hypercholesterolemia (HeFH). Use in children younger than 10 is not established.


Q: Does Atorvasterol affect nutrient absorption?

Official product information notes that co-administration with an aluminum- and magnesium-containing antacid can decrease the plasma concentration of Atorvasterol itself. The official label does not specifically address the absorption of dietary nutrients.


Q: Is Atorvasterol sometimes used for purposes other than cholesterol control?

The official indication for use is related solely to lipid management and cardiovascular risk reduction. Any use of the medicine beyond these documented purposes is not addressed or regulated in the official product information.


Q: Can people with lactose intolerance take Atorvasterol?

The inactive ingredients (excipients) used in the tablet formulation frequently include lactose. This presence of lactose may be a consideration for individuals who have a diagnosed lactose intolerance.


Q: Does the time of day a person takes Atorvasterol influence its effectiveness?

Official administration instructions state that the medicine may be taken at any time of the day. The effectiveness of the therapy is documented to remain the same regardless of the time of daily administration.

How should Atorvasterol be stored and disposed of?

How to Store and Dispose of Atorvastatin

Official Storage Requirements

Atorvastatin tablets must be stored at a controlled room temperature between 20°C and 25°C (68°F and 77°F). It is required to protect the medication from excess heat, moisture, and light. To maintain stability, the tablets must remain in the original container and the cap must be kept tightly closed.

Child Safety and Disposal

All forms of Atorvastatin must be stored in a location that is securely out of the reach and sight of children. For the oral suspension, any unused portion must be discarded after 60 days of opening. Unused or expired medication should be disposed of using an authorized drug take-back program. If a program is unavailable, mix the medication with an undesirable substance (e.g., coffee grounds) and place the mixture in a sealed container before discarding it in the household trash. The medication should not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atorvasterol found in:

A-Z Index: